Clinical Trial Update: A Drug-Drug Interaction Study of CYP3A4 Inhibition and Pan-CYP Induction on APX001 [Phase 1]

View source ↗

Summary

Phase 1 study assessing the interaction between CYP3A4 inhibition and pan-CYP induction on APX001 (fosmanogepix) has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fungal Infections

Drugs mentioned

• APX001 (fosmanogepix)

Snippet

Sponsor: Basilea Pharmaceutica | Conditions: Fungal Infection | Phase 1 | Status: COMPLETED